TTY Biopharm Co (ROCO:4105) Cyclically Adjusted Revenue per Share: NT$22.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4105 TTY Biopharm Co Ltd ROCO:4105
83 GF Score
Price NT$77.30
GF Value NT$87.18
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is TTY Biopharm Co Cyclically Adjusted Revenue per Share?

TTY Biopharm Co ROCO:4105 -0.39% 83 Cyclically Adjusted Revenue per Share is NT$22.99 as of Mar. 2026. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.18 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

TTY Biopharm Co's adjusted revenue per share for the three months ended in Mar. 2026 was NT$6.103. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$22.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TTY Biopharm Co's average Cyclically Adjusted Revenue Growth Rate was 6.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of TTY Biopharm Co was 6.20% per year. The lowest was 2.00% per year. And the median was 4.60% per year.

As of today (2026-08-12), TTY Biopharm Co's current stock price is NT$77.30. TTY Biopharm Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$22.99. TTY Biopharm Co's Cyclically Adjusted PS Ratio of today is 3.36.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TTY Biopharm Co was 5.06. The lowest was 3.14. And the median was 3.95.


TTY Biopharm Co  (ROCO:4105) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TTY Biopharm Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=77.30/22.99
=3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TTY Biopharm Co was 5.06. The lowest was 3.14. And the median was 3.95.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


TTY Biopharm Co Cyclically Adjusted Revenue per Share Related Terms


TTY Biopharm Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for TTY Biopharm Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTY Biopharm Co Cyclically Adjusted Revenue per Share Chart

TTY Biopharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.96 18.76 19.76 21.05 22.46

TTY Biopharm Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.52 21.92 22.36 22.46 22.99

ROCO:4105 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TTY Biopharm Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TTY Biopharm Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4105
83GF Score
TTY Biopharm Co Ltd ROCO:4105
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TTY Biopharm Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TTY Biopharm Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.103/330.2130*330.2130
=6.103

Current CPI (Mar. 2026) = 330.2130.

TTY Biopharm Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.867 241.018 5.298
201609 3.741 241.428 5.117
201612 3.824 241.432 5.230
201703 3.803 243.801 5.151
201706 3.741 244.955 5.043
201709 4.211 246.819 5.634
201712 4.645 246.524 6.222
201803 4.179 249.554 5.530
201806 4.009 251.989 5.253
201809 3.646 252.439 4.769
201812 4.381 251.233 5.758
201903 4.476 254.202 5.814
201906 4.383 256.143 5.650
201909 4.617 256.759 5.938
201912 4.459 256.974 5.730
202003 4.399 258.115 5.628
202006 3.642 257.797 4.665
202009 4.099 260.280 5.200
202012 4.822 260.474 6.113
202103 3.872 264.877 4.827
202106 4.254 271.696 5.170
202109 4.267 274.310 5.137
202112 5.884 278.802 6.969
202203 4.165 287.504 4.784
202206 4.676 296.311 5.211
202209 5.335 296.808 5.935
202212 6.153 296.797 6.846
202303 4.684 301.836 5.124
202306 5.068 305.109 5.485
202309 5.749 307.789 6.168
202312 6.595 306.746 7.100
202403 5.115 312.332 5.408
202406 5.515 314.175 5.797
202409 6.173 315.301 6.465
202412 6.860 315.605 7.178
202503 5.858 319.799 6.049
202506 6.056 322.561 6.200
202509 7.309 324.800 7.431
202512 6.650 324.054 6.776
202603 6.103 330.213 6.103

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$22.99 mean?
TTY Biopharm Co (ROCO:4105) has a Cyclically Adjusted Revenue per Share of NT$22.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TTY Biopharm Co and its competitors.
Is TTY Biopharm Co's Cyclically Adjusted Revenue per Share too high?
TTY Biopharm Co's current Cyclically Adjusted Revenue per Share is NT$22.99. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Cyclically Adjusted Revenue per Share compare to ZTS?
TTY Biopharm Co's Cyclically Adjusted Revenue per Share of NT$22.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TTY Biopharm Co and its competitors. TTY Biopharm Co's current Cyclically Adjusted Revenue per Share is NT$22.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.18, compared to a current price of NT$77.30 — trading 11.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$22.99. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Cyclically Adjusted Revenue per Share is NT$22.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?

Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued. The current stock price of NT$77.30 is trading 11.3% below its estimated GF Value™ of NT$87.18. GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.

Key valuation signals for ROCO:4105:

  • Cyclically Adjusted Revenue per Share: NT$22.99
  • GF Value™: NT$87.18 vs. price of NT$77.30 (11.3% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TTY Biopharm Co Business Description

Address No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score

Get the complete analysis for ROCO:4105

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.30
Price
NT$87.18
GF Value